Sacituzumab Govitecan in Primary HER2-negative Breast Cancer
Sacituzumab Govitecan in Primary HER2-negative Breast Cancer
Active, not recruiting · NCT04595565 · Registry updated 2026-04-22Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Sacituzumab Govitecan in Primary HER2-negative Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder, triple-negative breast carcinoma | Active, not recruiting | Phase 3 | 2026-04-22 | NCT04595565 |
7 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
163 results · Page 1 of 7
Research sites
Swipe the table sideways for more columns.